VIA Pharmaceuticals (VIA Pharmaceuticals) Long-Term Capital Lease Obligation : $0.00 Mil (As of Dec. 2010)

View and export this data going back to 1998. Start your Free Trial

What is VIA Pharmaceuticals Long-Term Capital Lease Obligation?

VIA Pharmaceuticals's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2010 was $0.00 Mil.

VIA Pharmaceuticals Long-Term Capital Lease Obligation Historical Data

The historical data trend for VIA Pharmaceuticals's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIA Pharmaceuticals Long-Term Capital Lease Obligation Chart

VIA Pharmaceuticals Annual Data

Trend

Dec01

Dec02

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

VIA Pharmaceuticals Quarterly Data
	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	-	-

VIA Pharmaceuticals (GREY:VIAP) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

VIA Pharmaceuticals Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of VIA Pharmaceuticals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

VIA Pharmaceuticals (VIA Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIA Pharmaceuticals Inc (GREY:VIAP) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

750 Battery Street, Suite 330, San Francisco, CA, USA, 94111

Website

http://www.baycitycapital.com

VIA Pharmaceuticals Inc is a development stage biotechnology company focuses on the development of small-molecule drugs to treat cardiovascular and metabolic diseases.

Executives

Fred B Craves	director	750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv, L.p.	10 percent owner	750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Management Iv Llc	10 percent owner	750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv Co Invesment Fund Lp	10 percent owner	750 BATTERY ST STE 400, SAN FRANCISCO CA 94111
Bay City Capital Llc	10 percent owner	750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111
Douglas B Given	director	C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Karen Steil Wright	officer: V.P. ? Finance, Controller	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Lawrence Kenneth Cohen	director, officer: CEO and President	750 BATTERY STREET, SUITE 330 SAN FRANCISCO CA 94111
Richard L Anderson	director	14031 216TH WAY NE, WOODINVILLE WA 98072
Mark Bagnall	director	3876 BAY CENTER PLACE, HAYWARD CA 94545
Rebecca Taub	officer: SVP, Research & Development	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Adeoye Y Olukotun	officer: Chief Medical Officer	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Deerfield Special Situations Fund International Ltd	10 percent owner, other: Possible Member of 10% Group	BISON COURT, ROAD TOWN, TORTOLA D8 -
Deerfield Special Situations Fund, L.p.	10 percent owner, other: Possible Member of 10% Group	780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

VIA Pharmaceuticals (VIA Pharmaceuticals) Headlines

From GuruFocus

VIA Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 08-12-2009

VIA Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-12-2009